Anorectal Disorders Treatment Global Market Report 2024

The global anorectal disorders treatment market has grown strongly in recent years. It will grow from $3.91 billion in 2023 to $4.2 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to aging population, lifestyle factors, increased awareness, on-surgical interventions.

The global anorectal disorders treatment market is expected to see strong growth in the next few years. It will grow to $5.38 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to demand for patient education, changing dietary habits, demand for telemedicine, research and development activities. Major trends in the forecast period include technological advancements, endoscopy and imaging, public health initiatives.

The increasing elderly population is anticipated to drive the expansion of the anorectal disorder treatment market in the foreseeable future. This demographic constitutes older adults, typically defined as individuals aged 65 or above. Anorectal disorder treatment plays a crucial role in offering pain relief, improving hygiene, preventing recurrence, and enhancing the overall quality of life for the elderly population afflicted with anorectal disorders. For instance, in October 2022, the World Health Organization, a specialized health agency based in the US, reported that globally, one out of every six individuals would be 60 years or older by 2030, and this number is projected to reach 2.1 billion elderly people by 2050. Consequently, the escalating geriatric population is a significant driver behind the growth of the anorectal disorder treatment market.

The surge in colorectal cancer cases is projected to drive the growth of the anorectal disorder treatment market in the foreseeable future. Colorectal cancer, a malignancy originating in the colon or rectum, is the focal point of anorectal disorder treatment. This treatment aims to alleviate symptoms like pain, fistulas, and bowel irregularities resulting from the cancer or its treatment, ultimately enhancing patient comfort and quality of life. For instance, as of May 2023, the American Society of Clinical Oncology, a reputable US-based professional organization, estimates that approximately 153,020 adults in the US will receive a colorectal cancer diagnosis. This figure includes 106,970 new cases of colon cancer and 46,050 new cases of rectal cancer. Consequently, the escalating incidence of colorectal cancer is a driving force behind the expansion of the anorectal disorder treatment market.

The stigma surrounding hemorrhoid treatment is anticipated to serve as a barrier to the growth of the anorectal disorders treatment market in the foreseeable future. This stigma arises from the reluctance of individuals to openly discuss their symptoms, often feeling embarrassed or fearing judgment for having hemorrhoids. For example, in 2022, as reported by the National Library of Medicine, a prominent US-based medical library, the hemorrhoid condition carries a certain stigma, making it challenging for individuals to seek treatment or engage in conversations about it. Consequently, the existing stigma surrounding hemorrhoid treatment poses a hindrance to the advancement of anorectal disorders treatment.

Prominent companies in the anorectal disorder treatment market are introducing novel medications and securing approvals to strengthen their market presence. This surge in drug development is broadening the spectrum of treatment options available for anorectal disorders, offering patients more precise and efficacious treatment choices, exemplified by the introduction of Budesonide 2mg Rectal Foam. For instance, in April 2023, Padagis US LLC, a reputable US-based pharmaceutical manufacturer, unveiled Budesonide 2mg Rectal Foam (a generic version of Uceris), an FDA-approved treatment for anorectal disorders. Uceris is a prescription corticosteroid medication utilized to manage active, mild-to-moderate cases of ulcerative colitis, an inflammatory bowel disease (IBD) that primarily affects the rectum and extends from the rectum to the sigmoid colon.

In June 2023, Merck and Co. Inc., a prominent US-based pharmaceutical company, completed the acquisition of Prometheus Biosciences Inc. for a sum of $10.8 billion. This strategic move is set to fortify Merck's immunology pipeline and bolster its presence in the field of immune-mediated diseases. Prometheus Biosciences Inc. is a distinguished biotechnology company based in the US, specializing in the development of products and treatments for inflammatory bowel disease, which encompasses anorectal disorders.

Major players in the anorectal disorders treatment market are Cardinal Health Inc., Cigna Corporation., Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca PLC, Merck and Co. Inc., Abbott Laboratories, GlaxoSmithKline PLC, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, McKesson Corporation, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Mylan N.V., B. Braun Melsungen AG, Bausch Health Companies Inc., Olympus Corporation, Sun Pharmaceutical Industries Ltd., Ethicon Inc., Coloplast A/S, Teleflex Incorporated, Cook Medical Inc., ConvaTec Group PLC, Lupin Limited, Akorn Inc., NATCO Pharma Limited.

North America was the largest region in the anorectal disorders treatment market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in anorectal disorders treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anorectal disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary approaches to anorectal disorder treatment include medications, surgical procedures, and other therapeutic methods. Medications are substances employed for diagnosing, managing, preventing, or alleviating a range of medical conditions and ailments. These conditions encompass diarrhea, hemorrhoids, abscesses, fistulas, itching, among others. Medications can be administered through oral, parenteral, rectal, or other routes. These treatment modalities are utilized by diverse end-users, including hospitals, specialty clinics, and other healthcare facilities.

This report provides anorectal disorders treatment market statistics, including anorectal disorders treatment industry global market size, regional shares, competitors with anorectal disorders treatment market share, detailed anorectal disorders treatment market segments, market trends and opportunities and any further data you may need to thrive in the anorectal disorders treatment industry. This anorectal disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anorectal disorders treatment market consists of revenues earned by entities by providing medical consultation, diagnostic tests and surgeries. The market value includes the value of related goods sold by the service provider or included within the service offering. The anorectal disorder treatment market also consists of sales of topical creams and ointments, wipes and cleansers and pads. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.